Changes of Swede Score in Low-Grade Cervical Precancerous Lesions After Administration of Coriolus versicolor Vaginal Gel: A Prospective Single-Arm Pilot Study in Indonesia.
- 2026-02-05
- International journal of women's health 18
- Sulaeman Andrianto Susilo
- Ali Budi Harsono
- PubMed: 41883943
- DOI: 10.2147/ijwh.s572630
Study Design
- Type
- Observational
- Population
- 22 women with VIA-positive low-grade precancerous lesions (Swede score <5)
- Methods
- Prospective, single-arm cohort study; colposcopy with Swede scoring and VIA at baseline, 3 and 6 months
- Duration
- 6 months
- Funding
- Unclear
Background
Coriolus versicolor vaginal gel has been extensively studied and shown to enhance the epithelialization of low-grade precancerous lesions and improve cervical microbiota. Swede score was used as tools in evaluating regression of the precancerous lesion. This study aims to evaluate the changes of Swede score on low-grade precancerous lesions after the use of Coriolus versicolor vaginal gel.Methods
This was a prospective, non-comparative cohort study conducted between July and December 2024. Twenty-two women with positive visual inspection with acetic acid (VIA) and low-grade colposcopic lesions (Swede score <5) were included. Colposcopy with Swede scoring and VIA were performed at baseline, 3 months, and 6 months. The primary endpoint was change in Swede score over time. Repeated measures were analyzed using non-parametric tests.Results
All participants were VIA-positive at baseline (22/22). At 3 months, 12/22 (54.5%) remained VIA-positive, decreasing to 6/22 (27.3%) at 6 months. Median Swede scores decreased from 3 (range 2-4) at baseline to 2 (0-4) at 3 months and 0 (0-5) at 6 months, with a statistically significant overall difference across timepoints (p<0.001).Conclusion
The use of Coriolus versicolor vaginal gel was associated with decreases in Swede score and increased VIA negativity over 6 months in this small, single-arm cohort.Research Insights
Median Swede scores decreased from 3 (range 2-4) at baseline to 2 (0-4) at 3 months and 0 (0-5) at 6 months, with a statistically significant overall difference across timepoints (p<0.001).
- Effect
- Beneficial
- Effect size
- Large
At 3 months, 12/22 (54.5%) remained VIA-positive, decreasing to 6/22 (27.3%) at 6 months.
- Effect
- Beneficial
- Effect size
- Large